PL2440177T3 - Farmaceutyczna postać dawkowania do doustnego podawania inhibitora rodziny Bcl-2 - Google Patents

Farmaceutyczna postać dawkowania do doustnego podawania inhibitora rodziny Bcl-2

Info

Publication number
PL2440177T3
PL2440177T3 PL10742875T PL10742875T PL2440177T3 PL 2440177 T3 PL2440177 T3 PL 2440177T3 PL 10742875 T PL10742875 T PL 10742875T PL 10742875 T PL10742875 T PL 10742875T PL 2440177 T3 PL2440177 T3 PL 2440177T3
Authority
PL
Poland
Prior art keywords
bcl
dosage form
oral administration
pharmaceutical dosage
family inhibitor
Prior art date
Application number
PL10742875T
Other languages
English (en)
Inventor
Claudia Packhaeuser
Norbert Steiger
Bernd Liepold
Drazen Kostelac
Martin Knobloch
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2440177(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of PL2440177T3 publication Critical patent/PL2440177T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10742875T 2009-06-08 2010-06-08 Farmaceutyczna postać dawkowania do doustnego podawania inhibitora rodziny Bcl-2 PL2440177T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18513009P 2009-06-08 2009-06-08
EP10742875.7A EP2440177B1 (en) 2009-06-08 2010-06-08 Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
PCT/IB2010/001659 WO2010143074A2 (en) 2009-06-08 2010-06-08 Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor

Publications (1)

Publication Number Publication Date
PL2440177T3 true PL2440177T3 (pl) 2016-03-31

Family

ID=43063251

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15184904T PL2982366T3 (pl) 2009-06-08 2010-06-08 Farmaceutyczna postać dawkowania do doustnego podawania inhibitora rodziny Bcl-2
PL10742875T PL2440177T3 (pl) 2009-06-08 2010-06-08 Farmaceutyczna postać dawkowania do doustnego podawania inhibitora rodziny Bcl-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15184904T PL2982366T3 (pl) 2009-06-08 2010-06-08 Farmaceutyczna postać dawkowania do doustnego podawania inhibitora rodziny Bcl-2

Country Status (38)

Country Link
US (5) US9642796B2 (pl)
EP (3) EP2440177B1 (pl)
JP (2) JP5872459B2 (pl)
KR (2) KR101751216B1 (pl)
CN (2) CN106074391A (pl)
AR (2) AR077021A1 (pl)
AU (1) AU2010258367B2 (pl)
BR (2) BRPI1012831B1 (pl)
CA (1) CA2763441C (pl)
CL (1) CL2011003054A1 (pl)
CO (1) CO6480964A2 (pl)
CR (1) CR20170037A (pl)
CY (1) CY1119663T1 (pl)
DK (2) DK2440177T3 (pl)
DO (2) DOP2011000375A (pl)
EC (1) ECSP12011580A (pl)
ES (2) ES2551860T3 (pl)
HK (2) HK1169613A1 (pl)
HR (2) HRP20151342T1 (pl)
HU (2) HUE025638T2 (pl)
IL (2) IL216494A (pl)
LT (1) LT2982366T (pl)
MX (1) MX2011013164A (pl)
MY (1) MY159824A (pl)
NO (1) NO2982366T3 (pl)
NZ (1) NZ597241A (pl)
PE (2) PE20160043A1 (pl)
PL (2) PL2982366T3 (pl)
PT (2) PT2982366T (pl)
RU (2) RU2568599C2 (pl)
SG (1) SG176264A1 (pl)
SI (2) SI2982366T1 (pl)
SM (1) SMT201500317B (pl)
TW (2) TWI540132B (pl)
UA (1) UA104471C2 (pl)
UY (1) UY32695A (pl)
WO (1) WO2010143074A2 (pl)
ZA (1) ZA201108853B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Bcl-2族群抑制劑之口服醫藥劑型
AU2011264993B2 (en) 2010-06-09 2014-02-06 Abbvie Bahamas Ltd. Solid dispersions containing kinase inhibitors
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
KR20180059560A (ko) * 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
AU2011332043C1 (en) 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
UY33746A (es) 2010-11-23 2012-06-29 Abbott Lab Método de tratamiento que usa inhibidores selectivos de bcl-2
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
US20160022708A1 (en) * 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2015051252A1 (en) * 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity
JP2017509337A (ja) * 2014-03-12 2017-04-06 ノバルティス アーゲー イムノコンジュゲートを作製する抗体を修飾するための特定部位
JP6831704B2 (ja) * 2014-06-18 2021-02-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 非イオン界面活性剤を含む新規の薬学的組成物
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
JP6577143B2 (ja) 2016-02-29 2019-09-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
US11872237B2 (en) 2018-12-28 2024-01-16 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and preparation method thereof
CA3160091A1 (en) 2019-11-05 2021-05-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
MX2022010410A (es) * 2020-02-24 2022-12-07 Guangzhou Lupeng Pharmaceutical Company Ltd Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.
EP4274562A1 (en) * 2021-01-08 2023-11-15 Syros Pharmaceuticals, Inc. Treatment regimens with fixed doses of tamibarotene
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用
TW202345857A (zh) * 2022-03-08 2023-12-01 美商昂科斯克塞爾醫療有限責任公司 他波司他之穩定調配物

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
GB9309509D0 (en) * 1993-05-07 1993-06-23 Merck Patent Gmbh Thrombin inhibitors
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
JPH09510182A (ja) * 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
PL364910A1 (pl) * 2001-01-31 2004-12-27 Pfizer Products Inc. Pochodne eterów użyteczne jako inhibitory izoenzymów PDE4
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
JP4598399B2 (ja) * 2002-02-04 2010-12-15 エラン ファーマ インターナショナル,リミティド 表面安定剤としてリゾチームを有するナノ粒子組成物
RU2318518C2 (ru) * 2002-02-26 2008-03-10 Астразенека Аб Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием
MY129850A (en) * 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US7318503B2 (en) 2004-04-26 2008-01-15 Akebono Corporation (North America) Pad retaining clips
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
NZ561609A (en) * 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
ES2385513T3 (es) 2005-10-11 2012-07-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composición para administración nasal
CN101346128B (zh) * 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
US7151188B1 (en) * 2005-11-16 2006-12-19 General Electric Company Process for the production of mercaptoalkylalkoxysilanes
US20080085313A1 (en) * 2006-05-15 2008-04-10 Given Bruce D Methods and compositions for treatment of sleep apnea
US20080004286A1 (en) * 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
JP5277168B2 (ja) * 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するbclインヒビター
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2351352C2 (ru) 2007-04-09 2009-04-10 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Твердая нанокомпозиция для доставки биологически активных веществ
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
MX2010003642A (es) * 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
EP2219651A1 (en) 2007-12-06 2010-08-25 Abbott Laboratories Oral compositions of abt-263 for treating cancer
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100280031A1 (en) 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Bcl-2族群抑制劑之口服醫藥劑型
KR20120052937A (ko) * 2009-06-18 2012-05-24 아보트 러보러터리즈 안정한 나노입자형 약물 현탁액
NZ598461A (en) * 2009-09-20 2013-12-20 Abbvie Inc Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
JP5779591B2 (ja) 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド Abt−263カプセル剤
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
CN103930595A (zh) 2011-11-11 2014-07-16 Sio2医药产品公司 用于药物包装的钝化、pH保护性或润滑性涂层、涂布方法以及设备

Also Published As

Publication number Publication date
JP2012529490A (ja) 2012-11-22
CL2011003054A1 (es) 2012-07-20
LT2982366T (lt) 2017-11-27
CN106074391A (zh) 2016-11-09
ZA201108853B (en) 2012-08-29
US20190269704A1 (en) 2019-09-05
US20220110951A1 (en) 2022-04-14
DOP2017000057A (es) 2017-04-16
WO2010143074A2 (en) 2010-12-16
TW201529572A (zh) 2015-08-01
CO6480964A2 (es) 2012-07-16
PL2982366T3 (pl) 2018-06-29
US20100310648A1 (en) 2010-12-09
SMT201500317B (it) 2016-02-25
DK2440177T3 (en) 2015-12-21
CY1119663T1 (el) 2018-04-04
KR101791404B1 (ko) 2017-10-30
KR20120027049A (ko) 2012-03-20
AR077021A1 (es) 2011-07-27
ES2651307T3 (es) 2018-01-25
SI2440177T1 (sl) 2016-01-29
CA2763441C (en) 2018-01-02
EP2440177A2 (en) 2012-04-18
SG176264A1 (en) 2012-01-30
PE20121084A1 (es) 2012-09-13
MX2011013164A (es) 2012-04-20
RU2568599C2 (ru) 2015-11-20
AU2010258367A1 (en) 2012-01-19
US20170189426A1 (en) 2017-07-06
IL238477A (en) 2017-01-31
DOP2011000375A (es) 2011-12-31
CN102802606A (zh) 2012-11-28
RU2015141869A (ru) 2018-12-29
RU2711359C2 (ru) 2020-01-16
RU2015141869A3 (pl) 2019-04-19
UY32695A (es) 2010-12-31
US9642796B2 (en) 2017-05-09
SI2982366T1 (en) 2018-01-31
TWI540132B (zh) 2016-07-01
HUE025638T2 (en) 2016-04-28
BRPI1012831A2 (pt) 2018-03-06
IL216494A (en) 2016-03-31
NZ597241A (en) 2014-01-31
US20210093649A1 (en) 2021-04-01
KR20170073714A (ko) 2017-06-28
TWI471321B (zh) 2015-02-01
BRPI1012831B1 (pt) 2021-05-18
KR101751216B1 (ko) 2017-06-28
ECSP12011580A (es) 2012-02-29
CA2763441A1 (en) 2010-12-16
HRP20171902T1 (hr) 2018-01-26
EP2982366B1 (en) 2017-09-13
CR20170037A (es) 2017-04-17
WO2010143074A3 (en) 2011-02-17
JP2016121159A (ja) 2016-07-07
EP3272334B1 (en) 2019-03-06
JP6129999B2 (ja) 2017-05-17
HRP20151342T1 (hr) 2016-01-01
MY159824A (en) 2017-02-15
PT2982366T (pt) 2017-12-21
AR109816A2 (es) 2019-01-23
NO2982366T3 (pl) 2018-02-10
ES2551860T3 (es) 2015-11-24
HUE035727T2 (en) 2018-05-28
EP3272334A1 (en) 2018-01-24
AU2010258367B2 (en) 2014-05-01
PT2440177E (pt) 2015-12-01
BR122018076978B1 (pt) 2021-08-31
DK2982366T3 (en) 2018-01-02
HK1169613A1 (en) 2013-02-01
JP5872459B2 (ja) 2016-03-01
EP2982366A1 (en) 2016-02-10
IL216494A0 (en) 2012-01-31
HK1220902A1 (zh) 2017-05-19
RU2011154143A (ru) 2013-07-20
UA104471C2 (uk) 2014-02-10
TW201103925A (en) 2011-02-01
IL238477A0 (en) 2015-06-30
EP2440177B1 (en) 2015-09-16
PE20160043A1 (es) 2016-02-11

Similar Documents

Publication Publication Date Title
HK1220902A1 (zh) 族群抑制劑之口服醫藥劑型
ME01614B (me) Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primjenu
IL193727A0 (en) Dosage forms for administering combinations of drugs
IL206159A0 (en) Oral pharmaceutical dosage forms
EP2429506A4 (en) DOSAGE FOR COATED PHARMACEUTICAL CAPSULES
IL231485A (en) Oral dosage forms of medicinal preparations are resistant to abuse
EP2395975A4 (en) ORAL PHARMACEUTICAL COMPOSITION OF DUTASTERIDE
ZA201105572B (en) Pharmaceutical composition for oral administration
EP2478904A4 (en) PHARMACEUTICAL COMPOSITION FOR PERORAL ADMINISTRATION OF DIINDOLYLMETHANE
EP2263637A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
EP2456439A4 (en) STABLE PHARMACEUTICAL OMEPRAZOLE FORMULATION FOR ORAL ADMINISTRATION
IL218643A0 (en) Orally disintegrating pharmaceutical dosage form containing aripiprazole
EP2651395A4 (en) PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION
EP2520300A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
HU0900482D0 (en) Pharmaceutical formulation for oral administration
HUE040419T2 (hu) Analgetikus gyógyászati kompozíció orális beadásra
SI2585051T1 (sl) Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
ZA201102405B (en) Pharmaceutical composition for oral administration
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION